Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

4  Enrolling
7  Total Trials
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-...
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-2
Drugs: Lebrikizumab
Age
6 months - 18 years
Phase
III
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: lebrikizumab, topical corticosteroid
Age
≥12 years
Phase
III
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-1
Drugs: Lebrikizumab, Topical corticosteroid
Age
6 months - 17 years
Phase
III
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: Ucenprubart
Age
18 - 70 years
Phase
II

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
3 
Completed Enrollment
7  Total Trials
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS)
Completed Enrollment
Conditions: Atopic Dermatitis (Eczema)
Trial Name
BREEZE-AD-PEDS
Drugs: Baricitinib, Placebo
Age
2 - 17 years
Phase
III
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Derm...
Completed Enrollment
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADmirable
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dup...
Completed Enrollment
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADapt
Drugs: Lebrikizumab
Age
≥12 years
Phase
III